Portal de recerca
ESTUDIO DE FASE 3, ALEATORIZADO, CONTROLADO CON PLACEBO Y DOBLE CIEGO DEL TRATAMIENTO DE MANTENIMIENTO CON IXAZOMIB POR VÍA ORAL DESPUÉS DEL TRATAMIENTO INICIAL EN PACIENTES CON MIELOMA MÚLTIPLE RECIÉN DIAGNOSTICADO Y NO TRATADO CON TRASPLANTE DE CÉLULAS MADRE.
Dades bàsiques
- Protocol:
- C16021
- EURDRACT:
- 2014-001394-13
- NCT:
- Centre:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Any inici:
- 2015
- Any de finalització:
- 2023
Documents
- No hi ha documents
Participants
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
[Farewell open letter to SEFH members].
Editorial Material. 10.7399/fh.2015.39.6.10128. 2015
2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11611. 2021
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro
Article. 10.33393/grhta.2022.2333. 2022
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Zozaya, Neboa; (...); Verde, Luis
Article. 10.1017/S0266462322000459. 2022
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.
de Andrés-Nogales F; (...); Martínez-Olmos J
Article. 10.1007/s41669-020-00201-2. 2020
A MULTI-STAKEHOLDER MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD STUDY.
Casado, MA; (...); Grp MULTIDEX-EMD
Meeting Abstract. 10.1016/j.jval.2018.09.2545. 2018
A new definition and refocus of pharmaceutical care: the Barbate Document
Morillo-Verdugo R; (...); Poveda-Andrés JL
Article. 10.7399/fh.11389. 2020
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients
Sanchez, MPM; (...); Montesinos, P
Article. 10.1007/s00277-021-04542-8. 2021
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Encinas, Cristina; (...); Martinez-Lopez, Joaquin
Article. 10.1038/s41408-022-00652-2. 2022
A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia
Megías-Vericat JE; (...); Aliño SF
Article. 10.1038/tpj.2015.80. 2016
ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation
Article. 10.1038/bmt.2016.264. 2017
Accuracy and prognostic impact of FDG PET/CT and biopsyin bone marrow assessment of follicular lymphomaat diagnosis: A Nation-Wide cohort study.
Rodenas-Quinonero, Isabel; (...); Ortuno, Francisco Jose
Article. 10.1002/cam4.5424. 2022
Acute hemolytic reaction by anti-Wra: Case report and review of the hemovigilance database of a tertiary care hospital.
Solves, Pilar; (...); de la Rubia, Javier
Article. 10.1016/j.transci.2021.103342. 2022
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols
Sitges, M; (...); Vives, S
Article. 10.1111/ejh.13417. 2020
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review
Review. 10.1177/20406207211038181. 2021
Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.
Ballesta-López O; (...); Poveda-Andrés JL
Article. 10.1177/1078155220915953. 2020
Adoptive transfer of ex-vivo expanded SARS-CoV-2-specific Cytotoxic Lymphocytes: a viable strategy for COVID-19 immunosuppressed patients?
Guerreiro M; (...); Piñana JL
Article. 10.1111/tid.13602. 2021
Aflibercept in exudative age related macular degeneration refractory to ranibizumab.
Ruiz Ramos J; (...); Gallego-Pinazo R
Article. 10.1016/j.oftal.2015.07.018. 2015
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Wong, Sandy W.; (...); Costa, Luciano J.
Meeting Abstract. 10.1182/blood-2022-159009. 2022
Analysing criteria for price and reimbursement of orphan drugs in Spain.
Badia, X; (...); Tort, M
Article. 10.7399/fh.11147. 2019
Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital
Valero García S; (...); Poveda Andrés JL
Article. 10.1177/10781552211038518. 2021
Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial.
Puig, Noemi; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8010. 2021
ANALYSIS OF PROGRESSION-FREE SURVIVAL OF AND GLOBAL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA OLDER THAN 65 YEARS CANDIDATES FOR AUTOLOGOUS PERIPHERAL BLOOD TRANSPLANTATION NON-CANDIDATES
Cejalvo, MJ; (...); De la Rubia, J
Meeting Abstract. 2017
ANALYSIS OF RESIDUAL DISEASE IN PERIPHERAL BLOOD BY MEANS OF MASS SPECTROMETRY IN PATIENTS WITH MULTIPLE MYELOMA OF THE GEM 2012 MINUS65. COMPARISON WITH THE IMWG STANDARD RESPONSE AND RESIDUAL DISEASE CRITERIA
Puig, N.; (...); Mateos, M., V
Meeting Abstract. 2021
Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype
Ibanez, M; (...); Cervera, J
Article. 10.1038/s41598-020-61589-9. 2020
ANALYSIS OF THE PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY PATIENTS (65 YEARS OLD) WITH MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION.
Cejalvo, MJ; (...); De la Rubia J
Meeting Abstract. 2018
Antimicrobial stewardship programme implementation in a medical ward
Ruiz, J; (...); Poveda, JL
Article. 2018
Antimicrobial stewardship programme in critical care medicine: A prospective interventional study
Ruiz, J; (...); Catellanos, A
Article. 10.1016/j.medin.2017.07.002. 2018
Assessment of the quality of sample labelling for clinical research.
Pérez-Huertas P; (...); Poveda-Andrés JL
Article. 10.7399/fh.2016.40.2.9753. 2016
Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial
Puig, Noemi; (...); Mateis, Maria-Victoria
Meeting Abstract. 10.1182/blood-2021-151557. 2021
Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
García-Sancho AM; (...); Caballero D
Article. 10.3324/haematol.2021.279426. 2022
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
Iglesias Gómez R; (...); Poveda Andrés JL
Article. 10.1136/ejhpharm-2021-002741. 2021
Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2018.12.027. 2019
Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial
Gonzalez-Calle, Veronica; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1182/blood-2022-162584. 2022
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort
De la Rubia, Javier; (...); Alegre, Adrian
Meeting Abstract. 10.1182/blood-2022-158538. 2022
Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura
Gomez-Segui, I, Izquierdo, CP, Comos, JD
Review. 10.1080/17474086.2021.1956898. 2021
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; (...); Hernandez D
Article. 10.1111/ctr.14550. 2022
BK Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation in the Pediatric Population
Perez-Huertas, P; (...); Poveda-Andres, JL
Article. 10.1177/1043454216631952. 2017
Breakthrough invasive fungal disease in high-risk hematologic malignancies in children: a single-center experience
Garcia-Robles, AA; (...); Fernandez-Navarro, JM
Meeting Abstract. 2017
BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone: final results of a phase 3 trial
Lahuerta Palacios, Juan Jose; (...); Blade, Joan
Meeting Abstract. 2022
Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2020.12.019. 2021
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.
Garces, Juan-Jose; (...); Paiva, Bruno
Article. 10.1200/JCO.21.01365. 2022
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country.
Muntañola A; (...); Bosch F
Letter. 10.1186/s40164-020-00195-x. 2020
Clinical Characteristics and Transfusion Management of Patients Diagnosed of Multiple Myeloma Receiving Daratumumab: Experience of a Single Centre
Arnao, M; (...); Sanz, G
Meeting Abstract. 10.1016/j.clml.2019.09.254. 2019
Clinical evaluation of rituximab treatment for neuromyelitis optica
Fernández-Megía MJ; (...); Poveda-Andrés JL
Article. 10.1016/j.nrl.2014.09.001. 2015
Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
Puig, Noemi; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1182/blood-2022-165441. 2022
Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model
Nogueras, A; (...); Calleja, MA
Letter. 10.1136/ejhpharm-2019-001905. 2019
Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing
Ibanez, Mariam; (...); Cervera, Jose
Meeting Abstract. 10.1182/blood.V128.22.598.598. 2016
Collaborative model of home delivery program in haemophilia through an association of patients
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic.
De La Puerta R; (...); Piñana JL
Article. 10.1038/s41409-021-01319-5. 2021
COMPARATIVE STUDY OF THE CLINICAL-BIOLOGICAL CHARACTERISTICS TO THE DIAGNOSIS AND RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA
Valenzuela, AV; (...); Ramos, IJ
Meeting Abstract. 2018
COMPARATIVE STUDY OF THE CHARACTERISTICS OF THE DIAGNOSIS AND RESPONSE TO TREATMENT IN PATIENTS AGED=60 YEARS VS. <60 YEARS WITH ACQUIRED PURPLE THROMBOTIC THROMBOCYTOPENIC. RESULTS OF THE SPANISH REGISTRATION OF PTT (REPTT)
Aracil Eva, Frances; (...); Comos Javier, De la Rubia
Meeting Abstract. 2021
Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo
Megias-Vericat, JE; (...); Poveda, JL
Meeting Abstract. 2020
COMPARISON OF THREE PANELS OF NGS APPLICATION IN ONCOHEMATOLOGY TO DISCARD SOMATIC AND/OR GERMINAL VARIANTS
Guzman-Gimenez, C.; (...); Such, E.
Meeting Abstract. 2021
Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation
Article. 10.1111/ejh.13270. 2019
CONCURRENT MUTATIONS IN ZRSR2 AND TET2 CAUSE SMD-COMPATIBLE ANOMALIES IN A MOUSE MODEL
Cristian, Garcia-Ruiz; (...); Alejandra, Sanjuan-Pla
Meeting Abstract. 2021
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Considering Bone Marrow Blasts from Nonerythroid Cells Improves the Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts
Arenillas, Leonor; (...); Florensa, Lourdes
Meeting Abstract. 2016
Considering Bone Marrow Blasts from Nonerythroid Cellularity Improves the Prognostic Evaluation of MDS in the Context of IPSS-R and Permits a Better Risk Assessment of MDS Patients Classified into the Intermediate Risk Category
Calvo, Xavier; (...); Florensa, Lourdes
Meeting Abstract. 10.1182/blood.V128.22.3185.3185. 2016
Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes
Arenillas L; (...); Florensa L
Article. 10.1200/JCO.2016.66.9705. 2016
Copper deficiency: a cause of misdiagnosis of myelodysplastic syndrome
Villalba, A; (...); Senent, L
Letter. 10.1007/s00277-018-3334-5. 2018
COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA
Gironella, M.; (...); Oyaguez, I
Meeting Abstract. 2019
Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units
Ruiz-Ramos, J; (...); Ramirez, P
Article. 10.1080/13696998.2017.1311903. 2017
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
Poveda JL; (...); Torres C
Article. 10.1080/14737167.2019.1635014. 2020
COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN
Trillo, JL; (...); Torres, C
Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018
COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN
Bonanad, S; (...); Gonzalez-Dominguez, A
Meeting Abstract. 2020
Costs of the management of hemophilia A with inhibitors in Spain
Bonanad, S; (...); Gonzalez-Dominguez, A
Article. 10.33393/grhta.2021.2234. 2021
Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1111/hae.13733. 2019
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
Eduardo Megias, Juan; (...); Iorio, Alfonso
Meeting Abstract. 10.1182/blood-2019-127946. 2019
Curative Strategy (GEM- CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
Mateos, Maria-Victoria; (...); San-Miguel, Jesus F.
Meeting Abstract. 10.1182/blood-2021-148423. 2021
Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
Mateos, Maria-Victoria; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-159606. 2022
Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis.
Puerta-Alcalde, Pedro; (...); Garcia-Vidal, Carolina
Article. 10.1093/mmy/myac038. 2022
Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
Solano de la Asuncion, Carlos; (...); Navarro, David
Letter. 10.1111/bjh.17732. 2021
Cytotoxic Natural Killer Subpopulations as a Prognostic Factor of Malignant Pleural Effusion
Lara, SH; (...); Suarez-Varela, MM
Article. 10.1007/s00408-018-0186-7. 2019
CHARACTERIZATION OF RECURRENTLY MUTATED GENES IN ACUTE MYELOID LEUKEMIA DE NOVO WITH NORMAL KARPOTYPE BY TARGETED MASSIVE SEQUENCING
Ibanez, M.; (...); Cervera, J.
Article. 2015
CHRONOLOGICAL AGE AS A PROGNOSTIC FACTOR IN PATIENTS WITH MULTIPLE MYELOMA NEW DIAGNOSIS NOT CANDIDATED FOR TRANSPLANTATION
Martinez Elena, Meseguer; (...); Comos Javier, De la Rubia
Meeting Abstract. 2021
Chronological age as a prognostic factor in transplant-ineligible patients with newly diagnosed Multiple Myeloma
Garcia Ruiz, Raquel; (...); de la Rubia, Javier
Meeting Abstract. 2021
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
Moreau, Philippe; (...); Goldschmidt, Hartmut
Letter. 10.1038/s41408-023-00805-x. 2023
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1080/17512433.2019.1573668. 2019
DEEP INTRONIC MUTATIONS IN THE RUNX1 AND FLT3 GENES PRODUCE OPENING SPLICING IN PATIENTS WITH MYELODYSPLASIC SYNDROMES
Mireia, Boluda-Navarro; (...); Jose, Cervera
Meeting Abstract. 2021
DEEP SEQUENCING OF 23 GENES DESIGNATED BY TCGA STUDY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE
Ibanez, M.; (...); Cervera, J.
Meeting Abstract. 2016
Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project
Blade, J; (...); Lizan, L
Article. 10.1136/bmjopen-2017-018850. 2018
Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies
Burgos, Leire; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2021-150092. 2021
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
Burgos, Leire; (...); Paiva, Bruno
Article. 10.1200/JCO.22.01916. 2023
Depth of Response of Isatuximab (Isa) plus Carfilzomib (K) and Dexamethasone (d) in Relapsed Multiple Myeloma: IKEMA Updated Analysis
Joseph, Mikhael; (...); Meletios, A. Dimopoulos
Article. 2022
Depth of response of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: IKEMA updated analysis
Hajek, Roman; (...); Dimopoulos, Meletios A.
Meeting Abstract. 2022
Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.
Salinas P; (...); Escaned J
Article. 10.1016/j.carrev.2021.11.015. 2021
Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia.
Gil, Jose Vicente; (...); Barragan, Eva
Article. 10.3390/ijms24054440. 2023
Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis
Alvarez-Roman, MT; (...); Badia, X
Article. 10.1177/2284240319880534. 2019
DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
Alvarez, E.; (...); Badia, F. J.
Meeting Abstract. 2019
DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN
Poveda, J. L.; (...); Vitoria, I
Meeting Abstract. 2019
Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain
Badia, X; (...); Poved, JL
Article. 10.1080/21678707.2019.1652163. 2019
Diffusion tensor imaging as a prognostic biomarker for motor recovery and rehabilitation after stroke
Puig, J; (...); Pedraza, S
Review. 10.1007/s00234-017-1816-0. 2017
Dose banding aplicado a la elaboracion de antineoplasicos: una revision narrativa de la literatura.
Pérez Huertas P; (...); Poveda Andrés JL
Article. 10.7399/fh.2015.39.4.8839. 2015
Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases
Megias-Vericat, JE; (...); Poveda, JL
Review. 10.1007/s10072-017-2833-9. 2017
Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan
Ribera, E; (...); Hernandez-Novoa, B
Article. 10.1016/j.eimc.2016.11.015. 2018
Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.
Torres Martínez E; (...); Vento M
Article. 10.1016/j.anpedi.2020.03.009. 2020
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
Palanques-Pastor T; (...); Poveda Andrés JL
Article. 10.1159/000517813. 2021
Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study
Ferra, Christelle; (...); Baltasar, Patricia
Meeting Abstract. 10.1182/blood-2022-162186. 2022
Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real World Setting in Spain: The Venares Study
Baltasar, Patricia; (...); Ferra, Christelle
Meeting Abstract. 10.1182/blood-2021-147685. 2021
EFFICACY OF IBRUTINIB IN THE TREATMENT OF LINFOPROLIFERATIVE SYNDROMES: EXPERIENCE IN REAL LIFE OF THE VALENCIAN COMMUNITY
Martin, EMD; (...); Castera, MJT
Meeting Abstract. 2018
eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice
Bonanad, S; (...); Megias-Vericat, JE
Meeting Abstract. 2018
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R; (...); Risitano AM
Article. 10.1056/NEJMoa2109965. 2022
ELTROMBOPAG ADDED TO STANDARD IMMUNOSUPPRESSION IMPROVES RESPONSE RATE IN SEVERE APLASTIC ANEMIA: RESULTS OF THE MULTICENTER PHASE III PROSPECTIVE RANDOMIZED RACE TRIAL
Risitano, A. M.; (...); de latour, R. Peffault
Meeting Abstract. 2021
EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN
Badia, F. J.; (...); Shepherd, J.
Meeting Abstract. 2019
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
Boluda B; (...); Montesinos P
Article. 10.1080/10428194.2021.1938031. 2021
Evolving treatment patterns and outcomes in older patients (=60 years) with AML: changing everything to change nothing?
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1038/s41375-020-01058-4. 2020
Experience of Home Delivery Program in Haemophilia Through an Association of Patients
Megias Vericat, J. E.; (...); Bonanad Boix, S.
Meeting Abstract. 2017
EXPERTS CONSENSUS ON THE FUTURE OF RARE DISEASES CARE AND ORPHAN DRUGS ACCESS IN SPAIN: A DELPHI STUDY
Paz S; (...); Urcelay J
Meeting Abstract. 10.1016/j.jval.2015.09.2016. 2015
Exploratory analysis for the implementation of antineoplastic logarithmic dose banding
Albert-Mari, A; (...); Poveda-Andres, JL
Article. 10.1007/s11096-018-0714-9. 2018
EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY
F, de Andres-Nogales; (...); Martinez, M.
Meeting Abstract. 2019
Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.1002/jca.21901. 2021
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Beltran, B; (...); Nos, P
Article. 10.1159/000492626. 2019
Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report
Fernandez-Sanchez, M; (...); Poveda-Andres, JL
Article. 10.1002/bdr2.1942. 2021
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J; (...); Bonanad, Santiago
Article. 10.1016/j.jgo.2022.10.016. 2022
GERMINAL PREDISPOSITION IN PATIENTS WITH MYELOID NEOPLASMS: ASSOCIATION BETWEEN MOLECULAR DISORDERS AND CLINICAL HISTORY
Marta, Santiago; (...); Jose, Cervera
Meeting Abstract. 2021
Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis
Editorial Material. 2022
Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12568. 2017
Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study
Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units
Article. 10.7399/fh.10935. 2018
Hazardous drugs: new challenges, new opportunities.
Valero García S; (...); Poveda Andrés JL
Article. 10.7399/fh.2016.40.2.10462. 2016
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.
Solana-Altabella A; (...); Montesinos P
Article. 10.1111/ejh.13604. 2021
High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.
El-Qutob D; (...); Carrera-Hueso FJ
Article. 10.1016/j.hrtlng.2022.02.003. 2022
High-permeability region size on perfusion CT predicts hemorrhagic transformation after intravenous thrombolysis in stroke
Puig, J; (...); Castellanos, M
Article. 10.1371/journal.pone.0188238. 2017
Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies
Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo
Article. 10.7399/fh.11729. 2022
Hospitalization budget impact during the COVID-19 pandemic in Spain.
Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.
Article. 10.1186/s13561-021-00340-0. 2021
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
de Arriba de la Fuente, Felipe, Montes Gaisan, Carmen, de la Rubia Comos, Javier
Review. 10.3390/cancers15010155. 2023
IBRUTINIB IN COMBINATION WITH R-GEMOX-D IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RECALLING OR REFRACTORY: PHASE II STUDY OF THE GELTAMO GROUP
Rey, Bua Beatriz; (...); Martin, A.
Meeting Abstract. 2020
Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)
Sancho, Juan-Manuel; (...); Guillermo Armando, Lopez
Meeting Abstract. 10.1182/blood-2019-125921. 2019
Immune biomarkers of survival and infection-related mortality in multiple myeloma (MM) patients treated with lenalidomide and dexamethasone (Rd)
Maia, Catarina; (...); Paiva, Bruno
Meeting Abstract. 2022
Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
Maia, Catarina; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-163058. 2022
Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors.
de la Asuncion Carlos, Solano; (...); Navarro, David
Letter. 10.1111/bjh.18655. 2023
Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-166826. 2022
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2016.1231405. 2017
Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart (R) in patients with multiple sclerosis
Edo Solsona MD; (...); Poveda Andrés JL
Article. 10.2147/PPA.S127508. 2017
IMPACT OF ADHERENCE ON SUBCUTANEOUS INTERFERON BETA-1A EFFECTIVENESS ADMINISTERED BY REBISMART (R) IN PATIENTS WITH MULTIPLE SCLEROSIS
Edo-Solsona, M.; (...); Poveda-Andres, J.
Meeting Abstract. 10.1016/j.jval.2016.09.512. 2016
IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)
Ibanez, Mariam; (...); Sanz, Guillermo
Meeting Abstract. 2020
Impact of an antimicrobial stewardship program on critical haematological patients.
Ruiz-Ramos, J; (...); Ramirez, P
Article. 10.7399/fh.2017.41.4.10709. 2017
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1038/tpj.2017.19. 2018
Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1097/FPC.0000000000000286. 2017
IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
Marco-Ayala, Javier; (...); Solves, Pilar
Article. 10.1016/j.jtct.2023.01.009. 2023
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
Martinez, Carmen; (...); Garcia-Sanz, Ramon
Article. 10.1007/s00277-022-05011-6. 2022
Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation
Ruiz J; (...); Aliño SF
Article. 10.3390/ijms160920168. 2015
Impact of t(11;14) according to induction regimen in newly diagnosed transplant-eligible multiple myeloma patients: long term follow-up of GEM05MENOS65 and GEM2012 PETHEMA/GEM studies
Moreno, David; (...); Rosinol, Laura
Meeting Abstract. 2021
Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
Badia X; (...); Hernández C
Article. 10.1186/s13023-020-01507-4. 2020
Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
Impact of voriconazole plasma concentrations on treatment response in critically ill patients
Ruiz, J; (...); Ramirez, P
Article. 10.1111/jcpt.12817. 2019
Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases
Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL
Article. 10.7399/fh.11262. 2020
Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients
Ruiz-Ramos, J; (...); Ramirez, P
Article. 10.1159/000478969. 2018
Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.
Onecha E; (...); Ayala R
Article. 10.1111/bjh.16432. 2020
Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis
Montesinos P; (...); Sanz MA
Article. 10.1038/bmt.2015.181. 2015
Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura
Pascual-Izquierdo, C; (...); Salinas, R
Article. 10.1002/jca.21894. 2021
Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Vericat, JEM; (...); Bonanad, S
Meeting Abstract. 2018
Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables
Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago
Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016
Infections of the Central Nervous System after Untelated Donor Umbilical Cord Blood Transplantation or Human teukocyte Antigen-Matched Sibling Transplantation
Balaguer Rosello A; (...); Sanz, J
Article. 10.1016/j.bbmt.2016.10.005. 2017
Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
Bastida, G; (...); Nos, P
Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2017.1323267. 2017
Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia.
Ruiz J; (...); Poveda JL
Article. 10.23736/S0026-4946.18.04978-2. 2018
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
INTENSIVE CHEMOTHERAPY VERSUS DECITABINE FIRST LINE LAM OVER 60 YEARS OLD
De la Fuente, A.; (...); Montesinos, P.
Meeting Abstract. 2019
Interdisciplinary recommendations document to improve adherence in patients with chronic inflammatory diseases: Adhing recommendations.
Bermejo San José F; (...); Sanromán-Álvarez L
Article. 10.7399/fh.2016.40.5.10180. 2016
Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12842. 2019
Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.
Solana-Altabella A; (...); Poveda JL
Article. 10.1177/1078155220904410. 2020
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP
Article. 10.1136/ejhpharm-2020-002322. 2020
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.
Hajek, Roman; (...); Dimopoulos, Meletios A.
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8034. 2021
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Dimopoulos, Meletios A.; (...); Hajek, Roman
Article. 10.1002/ajh.26602. 2022
ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results
Ghobrial, Irene; (...); Mateos, Maria-Victoria
Meeting Abstract. 2021
Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial
Rosinol, Laura; (...); Blade Creixenti, Joan
Meeting Abstract. 10.1182/blood-2021-146798. 2021
Late Breaking Abstract - Aldo-keto reductases expression correlate corticoids efficacy in vitro and on chronic rhinosinusitis with nasal polyps
Morell, Anselm; (...); Wsol, Vladimir
Meeting Abstract. 10.1183/13993003.congress-2021.PA891. 2021
Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab
Marco-Ayala, J; (...); Peris, MLS
Editorial Material. 10.5045/br.2020.2020059. 2020
LYFOMA POST-TRANSPLANT TYPE BURKITT: CLINICAL CHARACTERISTICS AND PRONOSTICAS IN A MULTICENTRAL STUDY
Varela, SB; (...); Bosch, F.
Meeting Abstract. 2017
Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.
Megías-Vericat JE; (...); Poveda-Andrés JL
Article. 2021
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.
Stahl M; (...); Zeidan AM
Article. 10.1038/s41375-020-0783-3. 2020
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
MASS SEQUENCING DIRECTED TO THE STUDY OF REARRANGEMENTS AND CHANGES IN GENIC EXPRESSION IN ACUTE MYELOID LEUKEMIA
Sargas Simarro, C.; (...); Barragan Gonzalez, E.
Meeting Abstract. 2019
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.
Puig, Noemi; (...); Mateos, Maria-Victoria
Article. 10.1182/bloodadvances.2021006762. 2022
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
Bonanad, S; (...); Santos, S
Article. 10.1007/s12325-021-01853-0. 2021
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Article. 10.3390/cancers14030596. 2022
Metyrapone as treatment in the neonatal McCune-Albright syndrome
de Mingo, Carmen; (...); Garcia-Robles, Ana
Article. 10.1515/jpem-2020-0036. 2020
MODELING OF IDH2 GENE MUTATIONS IN THE CAENORHABDITIS ELEGANS ORGANISM. DEVELOPMENT OF A NEW STUDY MODEL
Gonzalez-Romero, E.; (...); Cervera-Zamora, J.
Meeting Abstract. 2021
MOLECULAR APPROACH TO CHRONIC LYMPHOPROLIFERATIVE SYNDROMES IN THE DAILY CLINICAL PRACTICE OF A SINGLE CENTER
Mariam, Ibanez; (...); Irene, Luna
Meeting Abstract. 2021
MOLECULAR CHARACTERIZATION OF MULTIPLE MYELOMA PATIENTS BY USING A SINGLE ENRICHMENT PANEL IDENTIFYING SNVS, INDELS, CNVS AND TRANSLOCATIONS
Juan Manuel, Rosa-Rosa; (...); Joaquin, Martinez-Lopez
Meeting Abstract. 2021
Monitoring coagulation factors during surgery. A systematic review
Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11766. 2021
Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).
Valero-García S; (...); Delgado-Sánchez O
Article. 10.7399/fh.11655. 2021
Monitoring the quality of the hospital pharmacoterapeutic process by sentinel patient program.
Fernandez-Megia, MJ; (...); Poveda Andrés JL
Article. 10.7399/fh.10793. 2018
Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments
Gomez-Cebrian, N; (...); Pineda-Lucena, A
Review. 10.3390/cancers13184544. 2021
N. VICTOR JIMENEZ TORRES (1942-2015) IN MEMORIAM
Climente Martí M, Poveda Andrés JL, Culebras J
Biographical-Item. 10.3305/nh.2015.32.4.9704. 2015
National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)
Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel
Correction. 10.7399/fh.11740. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.
Rosa-Rosa, Juan Manuel; (...); Martinez-Lopez, Joaquin
Article. 10.3390/cancers14205169. 2022
Nivolumab for Heavily Pretreated Relapsed/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)
Martinez, C; (...); Garcia-Sanz, R
Meeting Abstract. 10.1182/blood-2018-99-115774. 2018
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Kim, Won-Seog; (...); Walewski, Jan
Meeting Abstract. 10.1182/blood-2022-158406. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice
Bonanad, S; (...); Poveda, JL
Meeting Abstract. 2018
P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results (vol 21, pg S109, 2021)
Ghobrial, Irene M.; (...); Mateos, Maria-Victoria
Correction. 10.1016/j.clml.2022.03.011. 2022
Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients
Ibanez, Mariam; (...); Luna I
Article. 10.3390/diagnostics12040953. 2022
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol
Garcia-Robles, Ana; (...); Carrascosa, MA
Article. 10.3389/fped.2020.00372. 2020
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Correction. 10.3389/fped.2021.834454. 2022
Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia.
Sanz J; (...); Piñana JL
Article. 10.1016/j.bbmt.2019.08.020. 2020
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project
Morillo-Verdugo, R; (...); Diaz-Olmo, J
Article. 10.7399/fh.11719. 2021
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.
Morillo-Verdugo R; (...); Díaz-Olmo J
Article. 2021
Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy
Margusino-Framiñán L; (...); Morillo-Verdugo R
Article. 10.7399/fh.11498. 2020
Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.2174/1389200218666171101124931. 2018
Pharmacogenomics and the treatment of acute myeloid leukemia
Megías-Vericat JE; (...); Aliño SF
Review. 10.2217/pgs-2016-0055. 2016
Pharmacometabolomics by NMR in Oncology: A Systematic Review.
Gómez-Cebrián N; (...); Pineda-Lucena A
Article. 10.3390/ph14101015. 2021
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: an agreement among hospital pharmacists for the standardized collection of a minimum set of data.
Calleja Hernández MÁ; (...); Aragon, B
Article. 10.7399/fh.2017.41.1.10463. 2017
Physical Activity In Haemophilia: Hemorrhagic Risk And Factor Levels (myPKFiT)
Querol-Fuentes, F; (...); Bonanad, S
Meeting Abstract. 2017
Pilot evaluation of home delivery programme in haemophilia
Megias-Vericat, JE; (...); Poveda-Andres, JL
Article. 10.1111/jcpt.12718. 2018
PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS
Vericat, JEM; (...); Iorio, A
Meeting Abstract. 2020
Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial
Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon
Meeting Abstract. 10.1182/blood-2019-125558. 2019
Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis
Megías-Vericat JE; (...); Aliño SF
Letter. 10.1038/tpj.2015.79. 2016
Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
Lazzari, Lorenzo; (...); Sanz, Jaime
Article. 10.1038/s41409-022-01725-3. 2022
Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
Article. 10.1080/10428194.2018.1474462. 2019
Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series
Bobillo, S; (...); Grp Espanol Linfomas Trasplante
Article. 10.1007/s00277-018-3473-8. 2018
Potential survival benefit for patients receiving allogeneic hematopoietic stem cell transplantation after nivolumab therapy for relapse/refractory Hodgkin lymphoma: Real-life experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO).
Martínez C; (...); García-Sanz R
Article. 10.1016/j.bbmt.2020.02.003. 2020
Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1007/s40261-019-00881-7. 2020
Practical guide to emergency treatment of thrombotic microangiopathy
Romero S; (...); Grupo de Microangiopatía Trombótica del Hospital Universitario y Politécnico La
Editorial Material. 10.1016/j.medcli.2018.01.013. 2018
Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process
Valero, S; (...); Poveda, JL
Article. 10.1016/j.yrtph.2018.03.001. 2018
Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters
Herrera Lara S; (...); Morales Suárez-Varela M
Article. 10.1007/s00408-017-0032-3. 2017
Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.
Minguela, Alfredo; (...); Periago, Adela
Article. 2021
PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019
Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)
Abrisqueta, Pau; (...); Bosch, Francesc
Meeting Abstract. 10.1182/blood-2019-128470. 2019
Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.
García-Robles A; (...); Aguar-Carrascosa M
Letter. 10.1016/j.anpedi.2020.06.008. 2021
Preparation and administration of insulin infusions in neonatology: A national survey.
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Article. 10.1016/j.anpede.2020.06.015. 2021
Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review
Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11780. 2021
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.
Tamariz-Amador, Luis-Esteban; (...); Troconiz, Inaki F.
Article. 10.1016/j.clml.2022.04.024. 2022
PROPOSED MOLECULAR CLASSIFICATION OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BASED ON SPLICING EVENTS
Liquori, A.; (...); Cervera Zamora, J.
Meeting Abstract. 2021
Prostaglandin Injection After Arterial Compromise Related to Hyaluronic Acid Filler
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1097/DSS.0000000000001046. 2017
Púrpura trombocitopénica trombótica inmune: sospecha y manejo básico en los servicios de urgencias. Revisión y consenso de un grupo de expertos de las sociedades científicas SEHH y SEMES.
Pascual-Izquierdo, Cristina; (...); de la Rubia Comos, Javier
Article. 10.55633/s3me/E099.2023. 2023
QUANTIFICATION OF CIRCULATING TUMOR CELLS IS THE MOST RELEVANT PROGNOSTIC FACTOR AT DIAGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA, WHO ARE TRANSPLANT CANDIDATES, Abstracts
Juan-Jose, Garces; (...); Bruno, Paiva
Meeting Abstract. 2021
Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker
Perez-Alenda, S; (...); Querol, F
Letter. 10.1111/hae.13388. 2018
Real-world effectiveness of caplacizumab vs standard of care in immune thrombotic thrombocytopenic purpura.
Pascual Izquierdo, Maria Cristina; (...); Del Rio-Garma, Julio
Article. 10.1182/bloodadvances.2022008028. 2022
Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura.
Mingot Castellano, Maria Eva; (...); Grp Espanol Aferesis GEA
Practice Guideline. 10.1016/j.medcli.2021.03.040. 2022
Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-167247. 2022
Reduction in alert fatigue in an assisted electronic prescribing system, through the Lean Six Sigma methodology.
Cuéllar Monreal MJ; (...); Poveda Andrés JL
Article. 10.7399/fh.2017.41.1.10434. 2017
RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group.
Bastos-Oreiro M; (...); López-Guillermo A
Article. 10.1007/s00277-020-03918-6. 2020
Renal response to rescue treatments in Relapsed Refractory Multiple Myeloma (RRMM) patients with renal impairment: final data of a large, observational, prospective study (MIR50)
Garcia-Guinon, Antonio; (...); de la Rubia, Javier
Meeting Abstract. 2021
Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia
Xicoy B; (...); Sanz G
Article. 10.1111/ejh.12679. 2016
Safety and efficacy of the BCR inhibitors after allogeneic stem cell transplantation for CLL
Yanez, L; (...); Bosch, F
Meeting Abstract. 2019
Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.
Article. 10.1111/ajt.14580. 2018
SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11565. 2020
SEQUENCING OF THE EXOME IN THE RECALLING OR REFRACTORY AML
Simarro Claudia, Sargas; (...); Eva, Barragan
Meeting Abstract. 2021
Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
Aguas Peris M; (...); Nos, P
Article. 10.1097/MIB.0000000000001182. 2017
Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice
Meeting Abstract. 2017
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study
Stefania Infante, Maria; (...); Grande, Carlos
Article. 10.1002/cam4.4293. 2021
Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic
Martinez-Lopez, Joaquin; (...); San-Miguel, Jesus F.
Meeting Abstract. 10.1182/blood-2021-149192. 2021
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics: a retrospective study of the PETHEMA/Spanish Myeloma Group (GEM)
Villalba, Ana; (...); De la Rubia, Javier
Meeting Abstract. 2022
SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization
Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis
Article. 10.1111/jcpt.13703. 2022
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.01.016. 2023
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity
Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar
Article. 10.1007/s00431-022-04628-z. 2022
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; (...); Gil A
Article. 10.1016/j.yebeh.2022.108711. 2022
The International Network for Evaluating Outcomes (iNeo) of neonates: evolution, progress and opportunities
Shah, Prakesh S.; (...); Int Network Evaluating Outcomes iN
Review. 10.21037/tp.2019.07.06. 2019
The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies
Strebel, Johanna A. Kremer Hovinga; (...); Scully, Marie
Meeting Abstract. 10.1182/blood-2022-156306. 2022
The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus
Torrent-Farnell, J; (...); Lizan, L
Article. 10.1016/j.healthpol.2018.03.002. 2018
Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.
Marques MR; (...); Mangas-Sanjuan V
Article. 10.1111/apa.14944. 2020
Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy
Del Rio-Bermudez, C; (...); Poveda, JL
Editorial Material. 10.1186/s40545-020-00276-6. 2020
Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.
Megías Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.rx.2015.01.008. 2015
Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
Bejar, S; (...); Mateu, PN
Meeting Abstract. 2020
Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bua, BR; (...); Garcia-Sancho, AM
Meeting Abstract. 2021
Use and handling safety of Mini-Spike 2 (R) chemo and puresite for safe chemotherapy compounding in a hospital pharmacy
Garcia, SV; (...); Andres, JLP
Article. 10.1016/j.yrtph.2018.10.002. 2018
Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients
García-Robles AA; (...); Poveda JL
Letter. 10.1016/j.jns.2016.04.048. 2016
USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Dominguez Hernandez, L.; (...); Gomez Segui, I
Meeting Abstract. 2019
VALIDATION OF DIFFERENT SYSTEMS OF STRATIFICATION OF PROGNOSIS OF SMD IN AN INDEPENDENT SERIES
Collado Jose, Esteban; (...); Sanz, Guillermo
Meeting Abstract. 2016
VALIDATION OF FREQUENT SPLICING EVENTS IN ACUTE MYELOID LEUKEMIA WITH POTENTIAL TO GENERATE NEOANTIGENS
Beatriz, Fernandez-Blanco; (...); Jose Vicente, Cervera Zamora
Meeting Abstract. 2021
Validation of the IMWG standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Jimenez Ubieto, Ana; (...); Lahuerta, Juan-Jose
Article. 10.1182/blood.2021012319. 2021
WHOLE GENE SEQUENCING FOR THE IDENTIFICATION OF SPLICING MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
Mireya, Morote-Faubel; (...); Jose, Cervera
Meeting Abstract. 2021